XELOX方案治疗晚期原发性肝癌的效果及对血清肿瘤标志物水平的影响.pdfVIP

XELOX方案治疗晚期原发性肝癌的效果及对血清肿瘤标志物

水平的影响

袁云;徐国辉

【摘要】ObjectiveToinvestigateefficacyofOxaliplatin+Capecitabine

(XELOX)chemotherapyintreatmentofadvancedprimarylivercancerand

itseffectonlevelsofserumtumormarkers.MethodsClinicaldataof78

patientswithadvancedprimarylivercancerbetweenJanuary2009and

January2013wasretrospectivelyanalyzed.Thepatientsweredividedinto

XELOXgroup(n=40)andFOLFOXgroup(Oxaliplatin+CalciumFolinate+

5-Fluorouracil,n=38)accordingtochemotherapyprotocol.Intwo

groups,chemotherapyeffectwascompared;changesoftumormarkers

levelssuchasserumalphafetoprotein(AFP),carcinoembryonicantigen

(CEA),tissuepolypeptideantigen(TPA)andcarbohydrateantigen(CA199)

beforeandafterchemotherapywererecorded;adversereactionsof

chemotherapywerestatisticallyanalyzed,andqualityoflifewas

compared.ResultsTherewasnosignificantdifferenceinthetotalremission

ratebetweenthetwogroups(P＞0.05).Aftertreatment,AFP,CEA,TPAand

CA199levelsweresignificantlylowerthanthosebeforechemotherapyin

thetwogroups(P＜0.05).InXELOXgroup,incidenceratesof1-5grade

hepaticandrenaltoxicityandgastrointestinalreactionsand1-2grade

bonemarrowsuppressionweresignificantlylowerthanthoseinFOLFOX

group(P＜0.05);timetoprogression(TTP)andprogression-freesurvival

(PFS)weresignificantlylongerthanthoseinFOLFOXgroup(P＜

0.05).ConclusionXELOXchemotherapyiseffectiveintreatmentofpatients

withadvancedprimarylivercancerwithlowerincidencerateofadverse

reactionandgoodsafety,anditcanimprovelongtermsurvivalqualityof

patients.%目的探讨奥沙利铂+卡培他滨(XELOX)方案治疗晚期原发性肝癌的临床

效果及对血清肿瘤标志物的影响.方法收集2009年1月-2013年1月78例晚期

原发性肝癌患者的临床资料,按化疗方案分为XELOX组(n=40)与FOLFOX组

(n=38,奥沙利铂+亚叶酸钙+5-氟尿嘧啶),比较两组化疗效果,记录化疗前后血清甲

胎蛋白(AFP)、癌胚抗原(CEA)、组织多肽抗原(TPA)、糖链抗原(CA199)等肿瘤标

志物水平的变化,统计化疗不良反应,比